SCHEMBL4069446

SCHEMBL4069446

COc1ccc(S(=O)(=O)N(Cc2cc3cccc(C)c3[nH]c2=O)CC2CCCO2)cc1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.74
KDM4E B2RXH2 10/20 0.74
HPGD P15428 5/20 0.74
GAA P10253 3/20 0.74
SMN1; SMN2 Q16637 1/20 0.70
HSD17B10 Q99714 10/20 0.64
HTT P42858 2/20 0.61
MAPK1 P28482 2/20 0.61
NPSR1 Q6W5P4 3/20 0.60
KMT2A Q03164 3/20 0.59
ALOX12 P18054 1/20 0.59
MEN1 O00255 1/20 0.59
RXFP1 Q9HBX9 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.57
POLB P06746 2/20 0.57
NPC1 O15118 1/20 0.57
LMNA P02545 1/20 0.57
CASP1 P29466 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5443440 0.90 HSD17B10 (0.75) ALDH1A1KDM4EHPGDGAASMN1; SMN2
SCHEMBL4074094 0.80 KDM4E (0.61) ALDH1A1KDM4EHPGDGAAHSD17B10
SCHEMBL4071631 0.80 KDM4E (0.70) ALDH1A1KDM4EHPGDGAAHSD17B10
SCHEMBL4074624 0.79 KDM4E (0.60) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL4077449 0.79 KDM4E (0.62) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL4081567 0.78 ALDH1A1 (0.67) ALDH1A1KDM4EHPGDGAASMN1; SMN2
SCHEMBL4081531 0.78 KDM4E (0.59) ALDH1A1KDM4EHPGDGAAHSD17B10
SCHEMBL4072759 0.76 ALDH1A1 (0.60) ALDH1A1KDM4EHPGDGAAHSD17B10
SCHEMBL4078823 0.76 HSD17B10 (0.80) ALDH1A1KDM4EHPGDGAAHSD17B10
SCHEMBL4080463 0.76 KDM4E (0.58) ALDH1A1KDM4EHPGDGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP claimed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US claimed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO claimed
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP disclosed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US disclosed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof ABCG2, ATP5ME, ATP5MG ALDH1A1 1055/4885KDM4E 2403/4885HPGD 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.